This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine (preprint)
biorxiv; 2021.
Preprint
in English
| bioRxiv | ID: ppzbmed-10.1101.2021.02.18.431484
ABSTRACT
Several promising vaccines for SARS-CoV-2 have received emergency use authorization in various countries and are being administered to the general population. However, many issues associated with the vaccines and the protection they provide remain unresolved, including the duration of conferred immunity, whether or not sterilizing immunity is imparted, and the degree of cross-variant protection that is achieved with these vaccines. Early evidence has suggested potentially reduced vaccine efficacy towards certain viral variants in circulation. Development of adjuvants compatible with these vaccine platforms that enhance the immune response and guide the adaptive and cellular immune responses towards the types of responses most effective for broad protection against SARS-CoV-2 will likely be pivotal for complete protection. Natural viral infection stimulates strong immune responses through the activation of three main pathways involving Toll-, RIG-I-, and NOD-like receptors (TLRs, RLRs, NLRs). As induction of appropriate innate responses is crucial for long-lasting adaptive immunity and for shaping the correct types of immune responses, we developed a combination, intranasal, adjuvant integrating a nanoemulsion-based adjuvant (NE) that activates TLRs and NLRP3 with an RNA agonist of RIG-I (IVT DI). This rationally designed combination adjuvant yielded a synergistic immune response with highly robust humoral and cellular responses towards SARS-CoV-2 using a recombinant spike protein S1 subunit antigen. Significantly enhanced virus neutralizing antibody titers were achieved towards both a homologous SARS-CoV-2 virus (IC50 titers of 1104) and a mouse-adapted variant containing the N501Y mutation present in the B1.1.7 UK and B.1.351 South Africa variants. Importantly, NE/IVT DI dramatically enhanced the TH1-biased cellular response, which is expected to provide more durable and tailored cellular immunity while avoiding potential vaccine enhanced pathology previously associated with TH2-biased responses in some SARS-CoV and MERS-CoV vaccines. Our previous work with the NE/IVT DI adjuvant has demonstrated its compatibility with a broad range of antigen types. Thus, this combined adjuvant approach has strong potential for improving the induced immune profile for a variety of SARS-CoV-2 vaccine candidates such that better protection against future drift variants and prevention of transmission can be achieved.
Full text:
Available
Collection:
Preprints
Database:
bioRxiv
Main subject:
Severe Acute Respiratory Syndrome
Language:
English
Year:
2021
Document Type:
Preprint
Similar
MEDLINE
...
LILACS
LIS